Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 健帆生物科技集团股份有限公司创建于1989年，专业从事生物材料和高科技医疗器械的研发、生产及销售，是以血液净化产品为主营业务的A股创业板上市公司（股票代码：300529）。目前公司市值稳居我国医疗器械上市公司前列，获评2017、2018、2019、2021年度“金牛最具投资价值奖”,连续4年获评“创业板上市公司50强”，2019年荣获“最佳股东回报上市公司”及财经风云榜创业板“竞争力企业”，入榜2020胡润中国百强大健康民营企业，企业纳税超4.5亿元。 健帆曾获“国家科技进步二等奖”“国家火炬计划重点高新技术企业”“中国技术市场协会金桥奖”、国家工信部“第六批制造业单项冠军示范企业”“国家技术创新示范企业”，是全国首批、广东省第二家通过医疗器械GMP检查的企业，入选国家产业振兴和技术改造项目、国家重大科技成果转化项目、广东省战略性新兴产业核心技术攻关项目及国家十二五科技支撑计划项目。2019年，公司被评选为“新中国成立70周年医药产业标杆企业”。公司产品已通过CE认证、ISO国际质量管理体系认证，连续十一年被评为广东省质量信用A类医疗器械生产企业，承担两项“国家重点新产品项目”和三项“国家级火炬计划项目”，获批组建国家企业技术中心、博士后科研工站、院土工作站、省级工程研究中心、省级企业重点实验室、省级工程技术研究开发中心、省级博士工作站。公司拥有强大的研发、生产能力以及遍布全国的销售网络，主营产品“DNA免疫吸附柱”“血浆胆红素吸附器”和“树脂血液灌流器”的市场占有率高。2019年，健帆生物血液净化机及血液灌流机入选第五批优秀国产医疗设备产品名录。公司自主投资新建的血液净化科研生产基地（健帆科技园）已于2015年胜利竣工并顺利投产。近两年，公司在京津、广深、湖北等地新设市场、科研中心和生产基地与现有的珠海健帆科技园生产基地一起形成华南、华中、华北的产业布局。 2025年，健帆将打造独有的“产品-服务-金融-‘+互联网’”多位一体的血液净化全价值链，实现集团化、品牌化、多元化发展，为成为“世界一流的高科技医疗技术企业集团”的企业愿景奠定坚实的基础。我们相信，高科技产品+高素质人才+高质量服务=不久将来的成功。
Main Business 专业从事生物材料和高科技医疗器械的研发、生产及销售
Legal Representative 董凡
Top Executives
董事长：董凡
董事：廖雪云,谢庆武,雷雯,李峰,唐先敏
独立董事：郭国庆,徐焱军,温志浩
Top 5 Shareholder
Shareholder name Nature Holding Date
董凡限售股+流通A股44.47%30/09/2024
唐先敏限售股+流通A股2.67%30/09/2024
中国银行股份有限公司－华宝中证医疗交易型开放式指数证券投资基金流通A股2.04%30/09/2024
香港中央结算有限公司流通A股1.59%30/09/2024
中国工商银行股份有限公司－易方达创业板交易型开放式指数证券投资基金流通A股1.50%30/09/2024
Company Secretary 黄聪
Solicitors 国浩律师（深圳）事务所
Auditors 瑞华会计师事务所（特殊普通合伙）
Tel No 0756-3619693
Fax No 0756-3619373
Website www.jafron.com
Email IR@jafron.com
Company Address
Register: 广东省珠海市高新区科技六路98号
Office: 广东省珠海市高新区科技六路98号
Listing Date 02/08/2016
Shares Capital
Shares Capital: 798,605,275
Total A Share: 798,605,275
Listed A Share: 512,488,200
Non-tradable A Share: 286,117,075
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.550
DPS(RMB)* ¥ 0.400
NBV Per Share(RMB)* ¥ 3.750
Market Capitalization(RMB) 14.714B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.